UA59371C2 - Проміжні сполуки та спосіб одержання оланзапіну, фармацевтична композиція - Google Patents
Проміжні сполуки та спосіб одержання оланзапіну, фармацевтична композиція Download PDFInfo
- Publication number
- UA59371C2 UA59371C2 UA99031635A UA99031635A UA59371C2 UA 59371 C2 UA59371 C2 UA 59371C2 UA 99031635 A UA99031635 A UA 99031635A UA 99031635 A UA99031635 A UA 99031635A UA 59371 C2 UA59371 C2 UA 59371C2
- Authority
- UA
- Ukraine
- Prior art keywords
- dihydrate
- olanzapine
- powder
- ray pattern
- pure
- Prior art date
Links
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 229960005017 olanzapine Drugs 0.000 title claims abstract description 26
- 239000013067 intermediate product Substances 0.000 title claims 2
- 238000004519 manufacturing process Methods 0.000 title abstract description 3
- 150000004683 dihydrates Chemical class 0.000 claims description 54
- 238000002441 X-ray diffraction Methods 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 15
- FUOBHGGXKJHKDF-UHFFFAOYSA-N 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine dihydrate Chemical group O.O.C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 FUOBHGGXKJHKDF-UHFFFAOYSA-N 0.000 claims description 12
- 230000004048 modification Effects 0.000 claims description 12
- 238000012986 modification Methods 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- LWSOZPNJUFEDJU-UHFFFAOYSA-N 2-[4-(1,3-benzoxazol-2-yl)-2-methoxyphenyl]acetonitrile Chemical compound C1=C(CC#N)C(OC)=CC(C=2OC3=CC=CC=C3N=2)=C1 LWSOZPNJUFEDJU-UHFFFAOYSA-N 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 16
- 239000000203 mixture Substances 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000002411 thermogravimetry Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003828 vacuum filtration Methods 0.000 description 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000039 congener Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JOMNTHCQHJPVAZ-UHFFFAOYSA-N 2-methylpiperazine Chemical compound CC1CNCCN1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 101100405318 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NSI1 gene Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- -1 dihydrate compound Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2648796P | 1996-09-23 | 1996-09-23 | |
| PCT/US1997/016499 WO1998012199A1 (en) | 1996-09-23 | 1997-09-18 | Intermediates and process for preparing olanzapine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA59371C2 true UA59371C2 (uk) | 2003-09-15 |
Family
ID=21832120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA99031635A UA59371C2 (uk) | 1996-09-23 | 1997-09-18 | Проміжні сполуки та спосіб одержання оланзапіну, фармацевтична композиція |
Country Status (35)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2420987A1 (en) * | 2000-08-31 | 2002-03-07 | Dr. Reddy's Laboratories Ltd. | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine |
| US6740753B2 (en) * | 2001-01-04 | 2004-05-25 | Geneva Pharmaceuticals, Inc. | Olanzapine crystal modification |
| AU2002340328A1 (en) * | 2001-10-29 | 2003-05-12 | Janet I. Cord | Olanzapine dihydrate-ii a process for its preparation and use thereof |
| AU2002367119A1 (en) | 2001-12-24 | 2003-07-15 | Sun Pharmaceutical Industries Limited | Crystalline form I of 2-methyl-4-(4-methyl-1-piperazinyl) 10H thieno [2,3-b][1,5]benzodiazepine |
| AU2003243153A1 (en) * | 2002-04-23 | 2003-11-10 | Dr. Reddy's Laboratories Limited | Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof |
| US7297789B2 (en) | 2002-05-31 | 2007-11-20 | Sandoz, Inc. | Process of preparation of olanzapine form I |
| SI21270A (sl) | 2002-07-15 | 2004-02-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Kristalne oblike olanzapina in postopki za njihovo pripravo |
| WO2004058773A1 (en) * | 2002-12-24 | 2004-07-15 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms |
| JP2007511605A (ja) * | 2003-11-18 | 2007-05-10 | スリーエム イノベイティブ プロパティズ カンパニー | オランザピン含有経皮薬物送達組成物 |
| ES2308304T3 (es) * | 2003-12-22 | 2008-12-01 | Teva Pharmaceutical Industries Ltd. | Procedimientos de preparacion de la olanzapina. |
| DE602005027308D1 (de) | 2004-01-27 | 2011-05-19 | Synthon Bv | Stabile salze von olanzapin |
| US20070072845A1 (en) * | 2004-02-19 | 2007-03-29 | Davuluri Rammohan Rao | Process for the preparation of olanzapine form 1 useful as antipsychotic drug |
| EP1781666A1 (en) * | 2004-07-14 | 2007-05-09 | Shasun Chemicals and Drugs Limited | Improved process for making form i of olanzapine. |
| ES2253091B1 (es) | 2004-07-27 | 2007-02-01 | Inke, S.A. | Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo. |
| US7829700B2 (en) | 2004-09-06 | 2010-11-09 | Shasun Chemicals And Drugs Limited | Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine |
| WO2006055603A2 (en) * | 2004-11-16 | 2006-05-26 | Elan Pharma International Ltd. | Injectable nanoparticulate olanzapine formulations |
| US7834176B2 (en) | 2006-01-26 | 2010-11-16 | Sandoz Ag | Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E |
| CA2591644A1 (en) * | 2007-06-14 | 2008-12-14 | Apotex Pharmachem Inc. | Novel processes to form-i of olanzapine |
| EP2486913A1 (en) | 2011-02-14 | 2012-08-15 | Labtec GmbH | Rapidly disintegrating oral film formulation for Olanzapin |
| JP6008734B2 (ja) * | 2012-12-20 | 2016-10-19 | 株式会社トクヤマ | オランザピンｉｉ型結晶の製造方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5302716A (en) * | 1986-01-16 | 1994-04-12 | Schering Corporation | Fused benzazepines |
| CA2002596A1 (en) * | 1988-11-14 | 1990-05-14 | Thomas M. Eckrich | Hydrates of b-lactam antibiotic |
| US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| GB9009229D0 (en) * | 1990-04-25 | 1990-06-20 | Lilly Industries Ltd | Pharmaceutical compounds |
| CA2097016A1 (en) * | 1992-05-29 | 1993-11-30 | John Fairhurst | Pharmaceutical compounds |
| US5550231A (en) * | 1993-06-15 | 1996-08-27 | Eli Lilly And Company | Loracarbef hydrochloride C1-C3 alcohol solvates and uses thereof |
| US5602124A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
| EG23659A (en) * | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
| US5637584A (en) * | 1995-03-24 | 1997-06-10 | Eli Lilly And Company | Solvate of olanzapine |
| EG24221A (en) * | 1995-03-24 | 2008-11-10 | Lilly Co Eli | Process for preparing olanzapine |
| US5631250A (en) * | 1995-03-24 | 1997-05-20 | Eli Lilly And Company | Process and solvate of 2-methyl-thieno-benzodiazepine |
| TR199900639T2 (xx) * | 1996-09-23 | 1999-06-21 | Eli Lilly And Company | Olanzapin dihidrat D. |
-
1997
- 1997-09-02 ZA ZA978515A patent/ZA978515B/xx unknown
- 1997-09-18 HU HU0000066A patent/HU226484B1/hu unknown
- 1997-09-18 TR TR1999/00640T patent/TR199900640T2/xx unknown
- 1997-09-18 CZ CZ0099099A patent/CZ299248B6/cs not_active IP Right Cessation
- 1997-09-18 ID IDW990058D patent/ID27275A/id unknown
- 1997-09-18 JP JP10514842A patent/JP2001500877A/ja not_active Withdrawn
- 1997-09-18 UA UA99031635A patent/UA59371C2/uk unknown
- 1997-09-18 KR KR1019997002424A patent/KR100560015B1/ko not_active Expired - Lifetime
- 1997-09-18 PL PL381478A patent/PL196069B1/pl unknown
- 1997-09-18 CA CA002265712A patent/CA2265712C/en not_active Expired - Lifetime
- 1997-09-18 WO PCT/US1997/016499 patent/WO1998012199A1/en not_active Ceased
- 1997-09-18 PL PL97332482A patent/PL194565B1/pl unknown
- 1997-09-18 RS YUP-155/99A patent/RS49598B/sr unknown
- 1997-09-18 EA EA199900326A patent/EA001642B1/ru not_active IP Right Cessation
- 1997-09-18 NZ NZ334448A patent/NZ334448A/en not_active IP Right Cessation
- 1997-09-18 IL IL12896297A patent/IL128962A/xx not_active IP Right Cessation
- 1997-09-18 BR BR9712100-2A patent/BR9712100A/pt not_active Application Discontinuation
- 1997-09-18 AU AU44841/97A patent/AU719441B2/en not_active Expired
- 1997-09-18 CN CN97198137A patent/CN1122036C/zh not_active Expired - Lifetime
- 1997-09-18 PL PL381479A patent/PL196068B1/pl unknown
- 1997-09-19 IN IN1736CA1997 patent/IN187156B/en unknown
- 1997-09-22 MY MYPI97004392A patent/MY125565A/en unknown
- 1997-09-22 ES ES97307383T patent/ES2166051T3/es not_active Expired - Lifetime
- 1997-09-22 CO CO97055061A patent/CO4910140A1/es unknown
- 1997-09-22 EP EP97307383A patent/EP0831098B1/en not_active Expired - Lifetime
- 1997-09-22 SV SV1997000081A patent/SV1997000081A/es not_active Application Discontinuation
- 1997-09-22 DE DE69708428T patent/DE69708428T2/de not_active Expired - Lifetime
- 1997-09-22 PT PT97307383T patent/PT831098E/pt unknown
- 1997-09-22 DK DK97307383T patent/DK0831098T3/da active
- 1997-09-22 AT AT97307383T patent/ATE209208T1/de active
- 1997-09-22 SI SI9730288T patent/SI0831098T1/xx unknown
- 1997-09-23 EG EG98697A patent/EG23861A/xx active
- 1997-09-23 AR ARP970104362A patent/AR013838A1/es not_active Application Discontinuation
- 1997-09-23 PE PE1997000855A patent/PE110398A1/es active IP Right Grant
- 1997-09-23 US US08/935,884 patent/US6020487A/en not_active Expired - Lifetime
-
1998
- 1998-02-27 TW TW086113832A patent/TW470746B/zh not_active IP Right Cessation
-
1999
- 1999-03-22 NO NO19991382A patent/NO323980B1/no not_active IP Right Cessation
-
2009
- 2009-06-05 JP JP2009135901A patent/JP2009242407A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA59371C2 (uk) | Проміжні сполуки та спосіб одержання оланзапіну, фармацевтична композиція | |
| EP0054951B1 (en) | Dibenz(b,f)(1,4)oxazepine derivatives, process for preparing the same, and pharmaceutical compositions comprising the same | |
| EP3517535B1 (en) | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | |
| DK169409B1 (da) | Vanduopløselige, farmaceutisk acceptable salte af substituerede derivater af rapamycin og farmaceutisk præparat indeholdende et sådant salt | |
| EP0134946B1 (en) | 3,6-Disubstituted-triazolo[3,4-a]phthalazine derivatives | |
| UA46840C2 (uk) | Дигідратна сіль мезилату 5-(2-4-(1,2-бензизотіазол-3-іл)-1-піперазиніл)етил)-6-хлор-1,3-дигідро-2h-індол-2-он, фармацевтична композиція для лікування психотичного розладу та спосіб лікування психотичного розладу у ссавців | |
| LT3200B (en) | Triazolopyridazine methodfor production thereof and use | |
| AU642829B2 (en) | Benzopyran intermediates | |
| KR20120091088A (ko) | 4,5,6,7-테트라클로로-3'',6''-다이하이드록시-2'',4'',5'',7''- 테트라요오도-3ｈ-스피로［이소벤조푸란-1,9''-잔텐］-3-온(로즈 벤갈) 및 관련 잔텐의 합성 방법 | |
| ATE108440T1 (de) | Arylaralkylether, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung. | |
| SE8206229L (sv) | Sett att framstella eburnamoninderivat | |
| EP0312773A3 (en) | Substituted 3-aminosydnonimines, process for their preparation and their use | |
| NO180297B (no) | Ikke-ioniske joderte forbindelser og kontrastmidler inneholdende de samme | |
| DE3365933D1 (en) | Substituted thienobenzodiazepinones, process for their preparation and medicines containing these compounds | |
| FI59595B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 5 eller 6-trifluormetyl 3-(4-alkylpiperazin-1-yl)karbonyloxi-2-(1,8-naftyridin-2-yl)isoindolin-1-oner | |
| SE8005127L (sv) | Sett att framstella 15-hydroxiimino-e-homoeburnanderivat | |
| NL8302288A (nl) | Eburnaan-oxim-ether-derivaten, werkwijze voor de bereiding ervan alsmede farmaceutische preparaten die deze derivaten bevatten. | |
| RU2670763C1 (ru) | Новые производные гелиомицина и фармацевтические композиции на их основе, ингибирующие опухолевый рост | |
| KR20250130622A (ko) | 피라졸로퀴나졸린계 화합물의 입체 이성질체와 중수소화 유도체 및 응용 | |
| FI115301B (fi) | Menetelmä 1,3-dihydro-6-hydroksi-2H-indol-2-oni-johdannaisten valmistamiseksi | |
| JPH02178282A (ja) | ジアザビシクロアルカン誘導体 | |
| FR2470116A1 (fr) | Derives benzylideniques, leur preparation et leur application en therapeutique | |
| JPH0459790A (ja) | ジエチレントリアミン三酢酸アルキルエステル化合物及びそれらの製造法 | |
| JPH0419998B2 (en:Method) | ||
| FR2550532A1 (fr) | Derives de l'indole, leur preparation et leur application en therapeutique |